Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | ALPL | P05186 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123130 | 0.80 | HSD17B10 (0.61) | HSD17B10ALPLALDH1A1MAPK1MEN1 | |
| SCHEMBL13343014 | 0.77 | HSD17B10 (0.58) | HSD17B10ALPLALDH1A1MAPK1MEN1 | |
| SCHEMBL7482231 | 0.77 | HSD17B10 (0.58) | HSD17B10ALPLALDH1A1MAPK1MEN1 | |
| SCHEMBL1220143 | 0.76 | HSD17B10 (0.56) | HSD17B10ALPLALDH1A1MAPK1MEN1 | |
| SCHEMBL1218889 | 0.76 | HSD17B10 (0.56) | HSD17B10ALPLALDH1A1MAPK1MEN1 | |
| SCHEMBL19398370 | 0.74 | HSD17B10 (0.70) | HSD17B10ALPLALDH1A1MAPK1MEN1 | |
| SCHEMBL7479968 | 0.72 | ALPL (0.73) | HSD17B10ALPLALDH1A1HPGDCYP3A4 | |
| SCHEMBL2575246 | 0.69 | TSHR (0.52) | ALDH1A1MAPK1HPGDTSHR | |
| SCHEMBL7490668 | 0.69 | ALPL (0.65) | HSD17B10ALPLALDH1A1HPGDCYP3A4 | |
| SCHEMBL7480743 | 0.69 | ALPL (0.72) | HSD17B10ALPLALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351275-B2 | Metal complexes with bisphophonate or pyrophosphate useful as imaging agents | DUKE UNIVERSITY (US) | 2022-06-07 | — | — | US | disclosed |
| CN-114213332-B | Tetrahydroindazole compound and preparation method and application thereof | 深圳市人民医院 | 2022-05-17 | — | — | CN | disclosed |
| CN-114213332-A | Tetrahydroindazole compound and preparation method and application thereof | 深圳市人民医院 | 2022-03-22 | — | — | CN | disclosed |
| US-20190231907-A1 | Metal Complexes with Bisphophonate or Pyrophosphate Useful as Imaging Agents | UNITED STATES GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
| US-20190194358-A1 | Synthetic Antibodies | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-27 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-7678803-B2 | Heat Shock Protein-90 inhibitors; Antiproliferative agents; cancer, inflammation, arthritis, angiogenesis, viral, fungal and malaria infections; 1-(isoquinoline, quinazoline or pyrimidino(3,2-d)pyridine-substituted)-4,5,6,7-tetrahydroindol-4-ones or 4,5,6,7-pyrazol-4-ones | SERENEX, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-100575341-C | The derivative of tetrahydro-indolone and the derivative of tetrahydro-indazolone and their application | GUOYAO LONGLI BIOLOG MEDICAL NEW TECHNOLOGY CO LTD BEIJING | 2009-12-30 | — | — | CN | disclosed |
| WO-2009140039-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008024974-A1 | PYRIMIDINE AND PYRAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| CN-1896060-A | Tetrahydro-indolone and tetrahydro-indazolone derivatives and their use | GUOYAO LONGLI BIOLOG MEDICAL N (CN) | 2007-01-17 | — | — | CN | disclosed |
| EP-1177185-B1 | 4, 5, 6, 7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-04-20 | — | — | EP | disclosed |
| US-6716856-B1 | CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA & TUBJOHN SPA (IT) | 2004-04-06 | — | — | US | disclosed |
| EP-1150998-A1 | PROCESS FOR THE PREPARATION OF CYCLIC TETRAPEPTIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047608-A1 | PROCESS FOR THE PREPARATION OF CYCLIC TETRAPEPTIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HDAC1, HDAC5, HDAC3 | HSD17B10 150/4885ALPL 1399/4885ALDH1A1 772/4885 |
| US-20190231907-A1 | Metal Complexes with Bisphophonate or Pyrophosphate Useful as Imaging Agents | PPIP5K2, MPI, PHPT1 | HSD17B10 4642/4885ALPL 710/4885ALDH1A1 4853/4885 |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | H1-5, NDUFS5, IL5 | HSD17B10 3696/4885ALPL 589/4885ALDH1A1 1920/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSD17B10 3780/4885ALPL 2081/4885ALDH1A1 1049/4885 |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | HSD17B10 3780/4885ALPL 2081/4885ALDH1A1 1049/4885 |
| US-11351275-B2 | Metal complexes with bisphophonate or pyrophosphate useful as imaging agents | PPIP5K2, MPI, PHPT1 | HSD17B10 4642/4885ALPL 710/4885ALDH1A1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.